These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 10099036)

  • 1. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects.
    Contreras F; Foullioux C; Pacheco B; Maroun C; Bolívar H; Lares M; Leal E; Cano R; Bermúdez V; Velasco M
    Am J Ther; 2008; 15(4):397-402. PubMed ID: 18645345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex.
    Charbit AR; Akerman S; Goadsby PJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):752-63. PubMed ID: 19657051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal and postjunctional components in the blood pressure effects of dopamine and bromocriptine in rabbits.
    Ensinger H; Majewski H; Hedler L; Starke K
    J Pharmacol Exp Ther; 1985 Sep; 234(3):681-90. PubMed ID: 2993590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical aspects of dopamine agonists and antagonists.
    Bianchine JR; Shaw GM; Greenwald JE; Dandalides SM
    Fed Proc; 1978 Aug; 37(10):2434-9. PubMed ID: 354976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine: receptors and clinical applications.
    Goldberg LI
    Clin Physiol Biochem; 1985; 3(2-3):120-6. PubMed ID: 3159532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine and dopamine receptors as target sites for cardiovascular drug action.
    Berkowitz BA
    Fed Proc; 1983 Oct; 42(13):3019-21. PubMed ID: 6137421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
    Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
    Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.
    Lahlou S
    Pharmacol Toxicol; 2001 May; 88(5):238-43. PubMed ID: 11393583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking.
    Monti JM; Jantos H
    Prog Brain Res; 2008; 172():625-46. PubMed ID: 18772053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced apomorphine sensitivity and increased binding of dopamine D2 receptors in nucleus accumbens in prepubertal rats after neonatal blockade of the dopamine D3 receptors by (+)-S14297.
    Flores-Tochihuitl J; Vargas G; Morales-Medina JC; Rivera G; De La Cruz F; Zamudio S; Flores G
    Synapse; 2008 Jan; 62(1):40-9. PubMed ID: 17957737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of dopamine receptors in the treatment of congestive heart failure.
    Goldberg LI
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S19-27. PubMed ID: 2478806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action.
    Blessing WW; Ootsuka Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):328-36. PubMed ID: 17055139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dopamine receptor agonists on the cAMP content in arteries of the rabbit.
    Zhu L; Zhao RR; Zhang WF
    Sheng Li Xue Bao; 2000 Jun; 52(3):247-51. PubMed ID: 11956574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems.
    Ziegler MG; Kennedy B; Holland OB; Murphy D; Lake CR
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):175-9. PubMed ID: 3158615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of prokinetic drugs inhibiting dopaminergic system on gallbladder motility in subjects with duodenal ulcer].
    Szabelska K; Chojnacki J; Grzegorczyk K; Mamos A
    Pol Merkur Lekarski; 1999 Apr; 6(34):188-91. PubMed ID: 10391057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of dopamine modulators on the cardiovascular and renal systems.
    Doggrell SA
    Expert Opin Investig Drugs; 2002 May; 11(5):631-44. PubMed ID: 11996645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors--physiological understanding to therapeutic intervention potential.
    Emilien G; Maloteaux JM; Geurts M; Hoogenberg K; Cragg S
    Pharmacol Ther; 1999 Nov; 84(2):133-56. PubMed ID: 10596903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs.
    Barrett RJ; Lokhandwala MF
    Eur J Pharmacol; 1983 Dec; 96(3-4):211-26. PubMed ID: 6676105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-synaptic nicotinic and D receptors functionally interact on dopaminergic nerve endings of rat and mouse nucleus accumbens.
    Grilli M; Zappettini S; Zoli M; Marchi M
    J Neurochem; 2009 Mar; 108(6):1507-14. PubMed ID: 19166510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.